Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Metab Syndr Relat Disord ; 18(2): 110-118, 2020 03.
Article in English | MEDLINE | ID: mdl-31976814

ABSTRACT

Background: Different studies have indicated that thiazide diuretics can increase the risk of developing type 2 diabetes (T2D). Therefore, in this study, we investigated whether switching from hydrochlorothiazide (HCTZ) to amlodipine resulted in ameliorating different cardiovascular and metabolic measures in hypertensive patients with or without T2D. Methods: This study [Diuretics and Diabetes Control (DiaDiC)] was a 6-week, single-blind, single-center randomized controlled trial. The first 20 normal glucose-tolerant, 20 prediabetic, and 20 T2D consecutive patients were randomized to continue the previous antihypertensive treatment with HCTZ (12.5-25 mg/day) or to switch from HCTZ to amlodipine (2.5-10 mg/day). The primary endpoints were the absolute change in 7-day continuous subcutaneous glucose monitoring (CSGM) glycemia, serum uric acid concentrations, and endothelial function [measured as flow-mediated dilation (FMD)]. Other secondary endpoints were investigated, including changes in glycated hemoglobin (HbA1c), glycemic variability from 7-day CSGM, and the estimated glomerular filtration rate (eGFR). Results: Amlodipine treatment was associated with a significant reduction in HbA1c (P = 0.03) for both 7-day CSGM glycemia (P = 0.01) and glycemic variability (coefficient of variability %: HCTZ +3%, amlodipine -2.8%), and a reduction in uric acid concentrations (P < 0.001), especially in participants with T2D or prediabetes. Following amlodipine treatment, a significant increase in both eGFR (P = 0.01) and FMD (P = 0.02) was also observed. Conclusions: This study demonstrates that the replacement of HCTZ with amlodipine has several metabolic and cardiovascular beneficial effects. However, further intervention studies are necessary to confirm the clinical effects of thiazides, especially in diabetic people and in those at risk of diabetes.


Subject(s)
Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus, Type 2 , Drug Substitution , Energy Metabolism/drug effects , Hydrochlorothiazide/therapeutic use , Hypertension/drug therapy , Sodium Chloride Symporter Inhibitors/therapeutic use , Aged , Amlodipine/adverse effects , Antihypertensive Agents/adverse effects , Biomarkers/blood , Calcium Channel Blockers/adverse effects , Diabetes Mellitus, Type 2/diagnosis , Female , Humans , Hydrochlorothiazide/adverse effects , Hypertension/blood , Hypertension/diagnosis , Hypertension/physiopathology , Italy , Male , Middle Aged , Single-Blind Method , Sodium Chloride Symporter Inhibitors/adverse effects , Time Factors , Treatment Outcome
2.
J Diabetes Res ; 2017: 9294038, 2017.
Article in English | MEDLINE | ID: mdl-28840131

ABSTRACT

There is actually no consensus about the possibility that in some instances, obesity may be a benign metabolically healthy (MH) condition as opposed to a normal-weight but metabolically unhealthy (MUH) state. The aim of this study was to characterize MH condition and to investigate possible associations with metabolic and cardiovascular complications. One thousand nineteen people (range of age 18-90 years) of the cohort of the ABCD_2 study were investigated. Participants were classified as normal weight (BMI < 24.9 kg/m2) or overweight-obese (BMI ≥25 kg/m2); they were also classified as MH in the presence of 0-1 among the following conditions: (a) prediabetes/type 2 diabetes, (b) hypertension, (c) hypertriglyceridemia or low HDL cholesterolemia, and (d) hypercholesterolemia. MUH condition was diagnosed if ≥2 of the conditions listed were found. The prevalence of overweight/obese people was 71.1%, of whom 27.4% were found to be MH. In addition, 36.7% of the normal-weight participants were MUH. HOMA-IR, high sensitivity C-reactive protein, and the carotid intima-media thickness were significantly different in the 4 subgroups (P < 0.001), with higher values observed in the MUH normal-weight and obese groups. In conclusion, this study highlights the importance of identifying a MH condition in normal-weight and in obese people in order to offer better treatment.


Subject(s)
Ideal Body Weight/physiology , Metabolic Diseases/epidemiology , Metabolic Diseases/metabolism , Obesity, Metabolically Benign/epidemiology , Obesity, Metabolically Benign/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Body Mass Index , Cohort Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Female , Humans , Hypertension/complications , Hypertension/epidemiology , Hypertension/metabolism , Hypertension/physiopathology , Italy/epidemiology , Longitudinal Studies , Male , Middle Aged , Obesity/complications , Obesity/epidemiology , Obesity/metabolism , Obesity/physiopathology , Overweight/complications , Overweight/epidemiology , Overweight/metabolism , Overweight/physiopathology , Prediabetic State/complications , Prediabetic State/epidemiology , Prediabetic State/metabolism , Prediabetic State/physiopathology , Young Adult
3.
Int J Food Sci Nutr ; 66(4): 426-38, 2015.
Article in English | MEDLINE | ID: mdl-25830946

ABSTRACT

The objective of this study was to validate two interviewer-led food frequency questionnaires (FFQs) of very different lengths: a medium-length FFQ (medium-FFQ) of 36 items and a short-length FFQ (short-FFQ) of 18 items, intending to measure levels of intakes in a local population. Both FFQs were validated against intakes derived from a 3-day dietary record (3-day DR). Sixty-five non-diabetic adults with no known cardiovascular, renal or other systemic diseases were included. High correlation coefficients between the FFQ and the 3-day DR (0.45-0.73) were observed for energy intake, carbohydrates and lipid and protein intake. Bland-Altman plots showed good agreement between the methods. Low (0.26-0.37) correlation coefficients of the different nutrient intakes obtained with the short-FFQ and the 3-day DR were observed, with the exception of alcohol intake (rho = 0.49). This study showed promising evidence for the use of a medium-FFQ as a potentially useful tool for investigating the relationship between habitual diet and diseases in clinical and research settings.


Subject(s)
Diet Surveys/statistics & numerical data , Feeding Behavior , Nutrition Assessment , Surveys and Questionnaires/standards , Adolescent , Adult , Aged , Diet/methods , Diet/statistics & numerical data , Diet Records , Diet Surveys/methods , Energy Intake , Female , Humans , Male , Middle Aged , Reproducibility of Results , Sicily , Young Adult
4.
Clin Nutr ; 32(3): 346-52, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23111004

ABSTRACT

BACKGROUND & AIMS: The role of glycemic index of the diet in glucose control and cardiovascular prevention is still not clear. The aim of this study was to determine the effects of hypocaloric diets with different glycemic indexes and glycemic loads on endothelial function and glycemic variability in nondiabetic participants at increased cardiovascular risk. METHODS: Forty nondiabetic obese participants were randomly assigned to a three-month treatment with either a low glycemic index (LGI; n=19) or high glycemic index (HGI; n=21) hypocaloric diet with similar macronutrient and fiber content. Endothelial function was measured as flow-mediated dilatation (FMD) of the brachial artery before and after dieting. In addition, 48-h continuous subcutaneous glucose monitoring was done before and after dieting in a subgroup of 24 participants. RESULTS: The amount of weight loss after dieting was similar in both groups. The glycemic index of the diet significantly influenced the FMD (P<0.005). In particular, the change of FMD was 2.3±2.6% following the LGI diet, and -0.9±3.6% after the HGI diet (P<0.005). The mean 48-h glycemia decreased significantly after dietary treatment (P<0.05), but no significant effect of the glycemic index of the diet on results was observed. The glycemic index of the diet significantly influenced the 48-h glycemic variability measured as coefficient of variability (CV%; P<0.001). The CV% decreased after the LGI diet (from 23.5 to 20.0%) and increased after the HGI diet (from 23.6 to 26.6%). The change in percentage of FMD was inversely correlated with the change in the 48-h glycemic CV% (r=-0.45; P<0.05). CONCLUSIONS: Endothelial function and glycemic variability ameliorate in association with the adherence to an LGI hypocaloric diet in nondiabetic obese persons. CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN56834511.


Subject(s)
Caloric Restriction , Cardiovascular Diseases/prevention & control , Endothelium/physiology , Glycemic Index , Obesity/diet therapy , Overweight/diet therapy , Adolescent , Adult , Blood Glucose , Body Composition , Body Fat Distribution , Body Mass Index , Brachial Artery/physiology , Brachial Artery/physiopathology , Cardiovascular Diseases/physiopathology , Diabetes Mellitus , Endothelium/physiopathology , Energy Intake , Female , Humans , Insulin/blood , Insulin Resistance , Male , Middle Aged , Obesity/physiopathology , Overweight/physiopathology , Risk Factors , Weight Loss , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...